NEW YORK/TOKYO -- The new Alzheimer's disease treatment developed by Tokyo-based Eisai and American partner Biogen has divided the U.S. medical community since its controversial approval in June, leading to slow initial sales for a drug viewed as a potential blockbuster.
Early uptake of aducanumab has been "a bit slower than what we assumed," Biogen CEO Michel Vounatsos said on an earnings call in July, about a month after approval.
